Multinational pharmaceutical executives out of the season: BMS head of oncology research and development joins Blueprint'...

Compilation . . New foreign biotechnology website Fierce Biotech personnel change column Chutes and Ladders recently released a summary of the recent personnel changes in the biopharmaceutical industry, Sina Pharmaceuticals compiled and collated this, the specific content is as follows: BMS oncology research and development head joined BlueprintBMS oncology research and development department head Fouad Namouni will join Blueprint Pharmaceuticals as president of research and development.
it is understood that Fouad Namouni served at BMS for 20 years, including leading the development team of immuno-oncology star drugs Opdivo and Yervoy.
Blueprint Pharmaceuticals is an innovative biopharmaceutical company that focuses on patient-driven cancer personalized therapies.
recently, the company's RET kinase inhibitor Gawreto (pralsetinib, Platinib) was approved by the U.S. FDA for the treatment of RET fusion-positive metastasis non-small cell lung cancer (NSCLC).
Pharmaceuticals owns the exclusive license of pralsetinib in Greater China.
September 7, pralsetinib was accepted by CDE and included in the priority review, which is expected to be the first RET-targeted therapeutic drug in the country.
joining Blueprint Pharmaceuticals, Fouad Namouni, president of research and development, will oversee the entire drug development cycle, from discovery to regulatory approval.
Dorsch, the company's chief scientific officer, and Dr. Andy Boral, chief medical officer, will continue to lead research and clinical development within the newly merged organization.
AbbVie veteran Dr Lisa Olson, who joined Magenta Therapeutics, will join Magenta Therapeutics as chief scientific officer (CSO), who has left and joined IFM Therapeutics.
Pharmaceuticals is a biotechnology company dedicated to the development of revolutionary bone marrow transplants for autoimmune diseases, blood cancers and genetic diseases.
has pioneered an integrated approach to pre-transplant preparation, stem cell collection, stem cell amplification, and post-transplant complications to expand the healing power of bone marrow transplantation to more patients by making the process more effective, safe, and easy.
over the past 15 years, Dr. Lisa Olson has held a variety of leadership positions at AbbVie's Biological Research Center, leading 15 molecules into the clinic, including the oral JAK inhibitor Rinvoq, which treats rheumatoid arthritis.
addition to the new CSO, Magenta Therapeutics has hired Dr Kevin Johnson to head its regulatory and quality department.
Kevin Johnson has held similar positions at Cydan's spin-off Rare Diseases, including Imara, which focuses on sickle cell disease, and Vtesse, which focuses on Neimanpike disease.
Sage Therapeutics Clinical Development Director joins Nocion Therapeutics Christopher Silber as Chief Medical Officer.
Nocion Therapeutics, a start-up focused on the development of sodium ion channel blocker-type analgesics, is currently bringing its first new drug project, NOC-100 (NTX-1175 of inhalant form), to clinical use.
NTX-1175 is a new type of small molecule charged sodium channel blocker (CSCB).
NOC-100 has the potential to treat chronic coughs and acute coughs, which are common symptoms in patients with COVID-19 and are associated with the spread of SARS-CoV-2 virus.
NOC-100 has the potential to reduce the spread of the disease between patients and hospital staff, family members, and caregivers by reducing cough symptoms in patients with COVID-19.
month, the UK MHRA quickly approved a Phase I study of the drug to accelerate Nocion's transition to a clinical phase company.
Christopher Silber has been a clinical development leader in the pharmaceutical industry for more than 20 years.
recently served as Senior Vice President at Sage, working in a variety of therapeutic areas, with extensive experience in clinical science and drug development, supporting regulatory approval of multiple products.
joining Nocion, he will lead clinical development activities for a range of diseases, including cough, specific dermatitis, and pain.
addition, there are other high-profile personnel changes: Reference source: Chutes and Ladders-Bristol Myers Squibb vet Noumani will head R and D at Blueprint Medicines